410 related articles for article (PubMed ID: 24443923)
21. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
[TBL] [Abstract][Full Text] [Related]
22. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
Goldstein SR; Bachmann GA; Koninckx PR; Lin VH; Portman DJ; Ylikorkala O;
Climacteric; 2014 Apr; 17(2):173-82. PubMed ID: 23984673
[TBL] [Abstract][Full Text] [Related]
23. Effects of ospemifene on bone in postmenopausal women.
de Villiers TJ; Altomare C; Particco M; Gambacciani M
Climacteric; 2019 Oct; 22(5):442-447. PubMed ID: 31294631
[TBL] [Abstract][Full Text] [Related]
24. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
25. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
26. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic evaluation of ospemifene.
McCall JL; DeGregorio MW
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):773-9. PubMed ID: 20429673
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
29. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
[TBL] [Abstract][Full Text] [Related]
30. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
31. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
Simon JA; Lin VH; Radovich C; Bachmann GA;
Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
[TBL] [Abstract][Full Text] [Related]
32. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
33. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
Constantine GD; Bouchard C; Pickar JH; Archer DF; Graham S; Bernick B; Mirkin S
J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
[TBL] [Abstract][Full Text] [Related]
34. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
Constantine GD; Goldstein SR; Archer DF
Menopause; 2015 Jan; 22(1):36-43. PubMed ID: 24977459
[TBL] [Abstract][Full Text] [Related]
35. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
37. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
38. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
39. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
40. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
